フルタミド
However, at low doses, these agents have shown to be both well tolerated and effective when used for the treatment of hirsutism [57]. [...] Table 8.2: Antiandrogens: [...] Androgen receptor blocker: [...] Type: Flutamide. Route: Oral. Dose: 250–500 mg/day."
↑ Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries (1 July 2013). Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge. Springer Science & Business Media. pp. 280–. ISBN 978-1-4614-7441-8. https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280
1 2 3 “Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines”.
(2015). doi:10.1038/onc.2015.55. PMID 25867062.
↑ Vincent DeVita; Theodore S. Lawrence; Steven A. Rosenberg (29 September 2015). Lymphomas and Leukemias: Cancer: Principles & Practice of Oncology. Wolters Kluwer Health. pp. 1029–. ISBN 978-1-4963-3828-0. https://books.google.com/books?id=n8ehCgAAQBAJ&pg=PT1029
1 2 3 “Flutamide”. 2022年3月22日閲覧。
↑ Analytical Profiles of Drug Substances and Excipients. Academic Press. (19 March 2001). pp. 155–. ISBN 978-0-08-086122-7. https://books.google.com/books?id=uEcv7SFDWBEC&pg=PA155
↑ W. Renée Acosta (1 October 2009). LWW's Foundations in Pharmacology for Pharmacy Technicians. Lippincott Williams & Wilkins. pp. 300–. ISBN 978-0-7817-6624-1. https://archive.org/details/lwwsfoundationsi0000acos
Patients with preexisting gynecomastia as a result of previous endocrine therapy with estrogens sustained no worsening of their gynecomastia and may have improved symptomatically." Keating et al.""
1 2 3 Neil Kaplowitz (16 October 2002). Drug-Induced Liver Disease. CRC Press. pp. 618–619. ISBN 978-0-203-90912-6. https://books.google.com/books?id=d8cgCAAAQBAJ&pg=PA618
↑ Thole, Zebron; Manso, Gloria; Salgueiro, Esther; Revuelta, Pilar; Hidalgo, Agustin (2004). “Hepatotoxicity Induced by Antiandrogens: A Review of the Literature”. Urologia Internationalis 73 (4): 289–295. doi:10.1159/000081585. ISSN 0042-1138. PMID 15604569.
1 2 3 “Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature”.
↑ “Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist”. Urol. Int. 66 (3): 135–9. (2001). doi:10.1159/000056592. PMID 11316974.
↑ “Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist”. J. Urol. 138 (4): 804–6. (October 1987). doi:10.1016/S0022-5347(17)43380-5. PMID 3309363.
↑ “A controlled trial of leuprolide with and without flutamide in prostatic carcinoma”. N. Engl. J. Med. 321 (7): 419–24. (August 1989). doi:10.1056/NEJM198908173210702. PMID 2503724.
↑ “Combination treatment in M1 prostate cancer”. Cancer 72 (12 Suppl): 3880–5. (December 1993). doi:10.